Scholarlink

Background <p>Ischemic heart disease (IHD) may share biological mechanisms with cancer, including ovarian cancer, through pathways such as chronic inflammation and oxidative stress. However, the relationship between IHD and ovarian cancer subtypes remains unclear. This study used Mendelian randomization (MR) to explore potential causal associations.</p> Methods <p>A two-sample MR analysis was conducted using genetic instruments for IHD from large-scale genome-wide association studies (GWAS). The inverse-variance weighted (IVW) method was used as the primary analysis, supported by MR-Egger, weighted median, and MR-PRESSO for sensitivity analyses.</p> Results <p>No significant association was found between IHD and overall ovarian cancer risk (OR = 0.97, 95% CI 0.92–1.03, P = 0.378). However, IHD was linked to a reduced risk of endometrioid ovarian cancer (OR = 0.86, 95% CI 0.76–0.98, P = 0.027). No associations were observed for serous, mucinous, or clear cell ovarian cancers. Sensitivity analyses confirmed robust findings.</p> Conclusions <p>IHD may confer a protective effect against endometrioid ovarian cancer but does not influence overall ovarian cancer risk. These findings highlight the need for further research into subtype-specific mechanisms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Causal role of ischemic heart disease in ovarian cancer subtypes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月21日

查看全文
  • Jianhai Chen,
  • Huabin He,
  • Ling Gao

摘要

Background

Ischemic heart disease (IHD) may share biological mechanisms with cancer, including ovarian cancer, through pathways such as chronic inflammation and oxidative stress. However, the relationship between IHD and ovarian cancer subtypes remains unclear. This study used Mendelian randomization (MR) to explore potential causal associations.

Methods

A two-sample MR analysis was conducted using genetic instruments for IHD from large-scale genome-wide association studies (GWAS). The inverse-variance weighted (IVW) method was used as the primary analysis, supported by MR-Egger, weighted median, and MR-PRESSO for sensitivity analyses.

Results

No significant association was found between IHD and overall ovarian cancer risk (OR = 0.97, 95% CI 0.92–1.03, P = 0.378). However, IHD was linked to a reduced risk of endometrioid ovarian cancer (OR = 0.86, 95% CI 0.76–0.98, P = 0.027). No associations were observed for serous, mucinous, or clear cell ovarian cancers. Sensitivity analyses confirmed robust findings.

Conclusions

IHD may confer a protective effect against endometrioid ovarian cancer but does not influence overall ovarian cancer risk. These findings highlight the need for further research into subtype-specific mechanisms.